Edition:
United States

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

25.03EUR
25 Apr 2017
Change (% chg)

-- (--)
Prev Close
€25.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
120,549
52-wk High
€30.20
52-wk Low
€11.50

Latest Key Developments (Source: Significant Developments)

Erytech to raise 70.5 million euros in private placement
Thursday, 13 Apr 2017 02:30am EDT 

Erytech Pharma SA : Erytech to raise 70.5 million euros ($75.19 million)in a private placement to U.S. aeuropean investors . Issue of 3,000,000 new shares at 23.50 euros, representing approximately 25.55% of company's issued share capital after completion of transaction . Expects to use proceeds from this capital increase to provide company with additional resources in order to fund continued clinical development of its product candidates .Intends to use approximately half of proceeds from proposed reserved offering to carry out preparatory steps for launch of potential phase 3 for pancreatic cancer indication.  Full Article

Erytech Pharma launches capital increase of c. 50 mln euros
Wednesday, 12 Apr 2017 01:07pm EDT 

Erytech Pharma SA : Launches capital increase by issuing new shares with par value of 0.10 euros per share .Capital increase, amounting to approximately 50 million euros ($53.0 million), is reserved for a certain category of investors.  Full Article

Erytech announces launch of investigator-initiated phase 2 study of eryaspase (GRASPA) for ALL
Tuesday, 4 Apr 2017 12:00pm EDT 

Erytech Pharma Sa : Announces launch of investigator-initiated phase 2 study of eryaspase (GRASPA) for ALL .Single arm, multi-center, multi-national phase 2 study is expected to enroll approximately 30 patients at 23 sites across seven Nordic and Baltic countries.  Full Article

Erytech reports positive Phase 2b data for eryaspase
Monday, 27 Mar 2017 01:30am EDT 

Erytech Pharma SA : Erytech reports positive Phase 2b data for Eryaspase for the treatment of metastatic pancreatic cancer . Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) . Statistically significant improvement of OS and pfs in entire patient population . Announced positive topline results from its phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA) .Multicenter, randomized Phase 2b study met its prespecified co-primary endpoints.  Full Article

Erytech Pharma FY net loss widens to 22.0 mln euros
Thursday, 2 Mar 2017 12:37pm EST 

Erytech Pharma SA : FY no revenue versus no revenue year ago . FY net loss amounts to 22.0 million euros ($23.1 million) versus a loss of 15.0 million euros a year ago . FY operating loss is 22.5 million euros versus a loss of 15.6 million euros a year ago .Cash position at Dec 31 37.7 million euros.  Full Article

Erytech Pharma H1 net loss widens to 10.3 mln euros
Tuesday, 6 Sep 2016 01:00pm EDT 

Erytech Pharma SA : H1 no revenue versus no revenue year ago . H1 net loss 10.3 million euros ($11.58 million) versus loss of 6.5 million euros year ago .H1 operating loss 10.6 million euros versus loss of 6.9 million euros year ago.  Full Article

Erytech Pharma cash position of 40.6 million euros at end of Q1
Tuesday, 10 May 2016 12:30pm EDT 

Erytech Pharma SA :Solid cash position of 40.6 million euros at Q1 quarter-end.  Full Article

Erytech Pharma presents additional results from trial with GRASPA
Tuesday, 8 Dec 2015 02:00am EST 

Erytech Pharma SA:Announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA.Says additional results add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL).  Full Article

Erytech Pharma raises about 25.4 mln euros in private placement
Monday, 7 Dec 2015 12:40pm EST 

Erytech Pharma SA:Erytech raises approximately 25.4 million euros in a private placement.  Full Article

Erytech Pharma raises about 25.4 mln euros in private placement
Thursday, 3 Dec 2015 02:31am EST 

Erytech Pharma SA:Raises about 25.4 mln euros within private placement with European and U.S. investors.Placement of 940,000 new shares with nominal value of 0.10 euro, at price of 27.00 euros, including share premium.Represents total of about 25.4 million euros or 14 pct of company's share capital.  Full Article

More From Around the Web

BRIEF-Erytech to raise 70.5 million euros in private placement

* Erytech to raise 70.5 million euros ($75.19 million)in a private placement to U.S. aeuropean investors